FIGURE 7.

Combination of vorinostat and Bay 117085 enhances vorinostat effectiveness in reducing tumor growth in nude mice implanted with ovarian cancer xenografts. A, average body weight of mice in four treatment groups (n = 7) (control, Bay 117085, vorinostat (Vor), and Bay 117085/vorinostat combination) over the course of 4 weeks. B, average tumor volumes in the four treatment groups (n = 7) over the course of 4 weeks. C, excised SKOV3 tumors implanted subcutaneously in mice (n = 7) after 4 weeks of treatment. D, average weight of the excised tumors (n = 7) at the end of the 4-week treatment period. The values represent the mean ± S.E. *, p < 0.05; **, p < 0.01.